8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 14, 2022

Voyager Therapeutics, Inc.

(Exact name of registrant as specified in itscharter)

Registrant’s telephone number, including area code:

(857) 259-5340

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election ofDirectors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 14, 2022, in consultation with the Nominating and Corporate Governance Committee (the “Committee”) of the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), Mark Levin and Steven Paul, M.D. each requested not to be nominated for re-election to the Board when his current term expires at the Company’s 2022 annual meeting of stockholders. Each director cited a desire to reduce his professional commitments and the number of boards of public companies on which he serves and confirmed that such request was not based upon any disagreement with the Board or with the management on any matter relating to the Company’s operations, policies or practices.

The Committee has engaged a search firm to identify candidates to fill the anticipated vacancies to be created by the departures of Mr. Levin and Dr. Paul following the Company’s 2022 annual meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.